English

rEVO Biologics, Inc.

EDGAR

Registration statement (S-1) · filed 2014-06-25

64 filing records in this dataset, filed from 1996-08-14 to 2014-06-25. Explore the available filing history and original sources.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

9.23 million USD

2010-09-30 · USD

Exact inputs and evidence

Revenue: 9227000 USD Source

Operating margin

44.51%

2010-09-30 · %

Exact inputs and evidence

Operating Income: 4107000 USD Source
Revenue: 9227000 USD Source

Cash and cash equivalents: 2.74 million USD 2010-09-30 Source
Exact value

2738000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2014-06-25.

Financial data available through: 2010-01-03.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2010-01-03
Operating income: 10 of 11 periods available· newest 2010-01-03
Net income: 10 of 11 periods available· newest 2010-01-03
Operating cash flow: 10 of 11 periods available· newest 2010-01-03
Capital expenditure: 10 of 11 periods available· newest 2010-01-03
Total assets: 10 of 11 periods available· newest 2010-01-03
Total liabilities: 10 of 11 periods available· newest 2010-01-03
Current assets: 10 of 11 periods available· newest 2010-01-03
Current liabilities: 10 of 11 periods available· newest 2010-01-03
Cash and cash equivalents: 10 of 11 periods available· newest 2010-01-03
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-83%

Prior period

USD 16.66 million

2007-12-29 – 2008-12-28
Current period

USD 2.83 million

2009-01-04 – 2010-01-03

Exact inputs and evidence

2826000 − 16656000 = -13830000 USD

16656000 USD · 2007-12-29 – 2008-12-28
Inspect prior input Prior source
2826000 USD · 2009-01-04 – 2010-01-03
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Year-over-year change in Revenue: -13830000 USD Concept: fundies:Revenue Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2826000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#4945 Input fundies:Revenue: 16656000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#4945
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 4.29 million

Prior period

−USD 22.67 million

2007-12-29 – 2008-12-28
Current period

−USD 26.95 million

2009-01-04 – 2010-01-03

Exact inputs and evidence

-26953000 − -22665000 = -4288000 USD

-22665000 USD · 2007-12-29 – 2008-12-28
Inspect prior input Prior source
-26953000 USD · 2009-01-04 – 2010-01-03
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Year-over-year change in Net income: -4288000 USD Concept: fundies:NetIncome Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -26953000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#5169 Input fundies:NetIncome: -22665000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#5169
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 9.34 million

Prior period

−USD 18.01 million

2007-12-29 – 2008-12-28
Current period

−USD 27.35 million

2009-01-04 – 2010-01-03

Exact inputs and evidence

-27348000 − -18010000 = -9338000 USD

-18010000 USD · 2007-12-29 – 2008-12-28
Inspect prior input Prior source
-27348000 USD · 2009-01-04 – 2010-01-03
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Year-over-year change in Operating cash flow: -9338000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -27348000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 Input fundies:OperatingCashFlow: -18010000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-29.6%

Prior period

USD 550,000

2007-12-29 – 2008-12-28
Current period

USD 387,000

2009-01-04 – 2010-01-03

Exact inputs and evidence

387000 − 550000 = -163000 USD

550000 USD · 2007-12-29 – 2008-12-28
Inspect prior input Prior source
387000 USD · 2009-01-04 – 2010-01-03
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Year-over-year change in Capital expenditure: -163000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 387000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 Input fundies:CapitalExpenditure: 550000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2010 2009-01-04 – 2010-01-03

Revenue USD 2.83 million 100% of revenue
Cost of revenue USD 1.18 million 42% of revenue
Operating expenses USD 36.82 million 1,303% of revenue
Other operating costs Derived USD 1.08 million 38% of revenue
Operating income −USD 36.25 million −1,283% of revenue
Tax, interest and other Derived −USD 9.3 million −329% of revenue
Net income −USD 26.95 million −954% of revenue

Cash

Operating cash flow −USD 27.35 million −968% of revenue
Capital expenditure USD 387,000 14% of revenue
Free cash flow Derived −USD 27.74 million −981% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2000 Operating loss: operating costs were 229% of revenue.
2001 Operating loss: operating costs were 350% of revenue.
2002 Operating loss: operating costs were 410% of revenue.
2003 Operating loss: operating costs were 414% of revenue.
2005 Operating loss: operating costs were 541% of revenue.
2006 Operating loss: operating costs were 817% of revenue.
2006 Operating loss: operating costs were 682% of revenue.
2007 Operating loss: operating costs were 362% of revenue.
2008 Operating loss: operating costs were 239% of revenue.
2010 Operating loss: operating costs were 1,383% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2000 2000-01-01 – 2000-12-31	12880000	29466000 Derived	-16586000	-2445000 Derived	-14141000	-5443000 Derived	Source 2000-01-01 – 2000-12-31: 12880000 USD Inspect Revenue Open source 2000-01-01 – 2000-12-31: -16586000 USD Inspect Operating Income Open source 2000-01-01 – 2000-12-31: -14141000 USD Inspect Net Income Open source 2000-01-01 – 2000-12-31: -3479000 USD Inspect Operating Cash Flow Open source 2000-01-01 – 2000-12-31: 1964000 USD Inspect Capital Expenditure Open source
2001 2000-12-31 – 2001-12-30	10379000	36288000 Derived	-25909000	-1589000 Derived	-24320000	-15422000 Derived	Source 2000-12-31 – 2001-12-30: 10379000 USD Inspect Revenue Open source 2000-12-31 – 2001-12-30: -25909000 USD Inspect Operating Income Open source 2000-12-31 – 2001-12-30: -24320000 USD Inspect Net Income Open source 2000-12-31 – 2001-12-30: -11984000 USD Inspect Operating Cash Flow Open source 2000-12-31 – 2001-12-30: 3438000 USD Inspect Capital Expenditure Open source
2002 2001-12-30 – 2002-12-29	9764000	40081000 Derived	-30317000	-780000 Derived	-29537000	-29573000 Derived	Source 2001-12-30 – 2002-12-29: 9764000 USD Inspect Revenue Open source 2001-12-30 – 2002-12-29: -30317000 USD Inspect Operating Income Open source 2001-12-30 – 2002-12-29: -29537000 USD Inspect Net Income Open source 2001-12-30 – 2002-12-29: -23075000 USD Inspect Operating Cash Flow Open source 2001-12-30 – 2002-12-29: 6498000 USD Inspect Capital Expenditure Open source
2003 2002-12-29 – 2003-12-28	9640000	39957000 Derived	-30317000	-780000 Derived	-29537000	-35241000 Derived	Source 2002-12-29 – 2003-12-28: 9640000 USD Inspect Revenue Open source 2002-12-29 – 2003-12-28: -30317000 USD Inspect Operating Income Open source 2002-12-29 – 2003-12-28: -29537000 USD Inspect Net Income Open source 2002-12-29 – 2003-12-28: -31771000 USD Inspect Operating Cash Flow Open source 2002-12-29 – 2003-12-28: 3470000 USD Inspect Capital Expenditure Open source
2005 2004-01-03 – 2005-01-02	6626000	35819000 Derived	-29193000	300000 Derived	-29493000	-21244000 Derived	Source 2004-01-03 – 2005-01-02: 6626000 USD Inspect Revenue Open source 2004-01-03 – 2005-01-02: -29193000 USD Inspect Operating Income Open source 2004-01-03 – 2005-01-02: -29493000 USD Inspect Net Income Open source 2004-01-03 – 2005-01-02: -19958000 USD Inspect Operating Cash Flow Open source 2004-01-03 – 2005-01-02: 1286000 USD Inspect Capital Expenditure Open source
2006 2005-01-02 – 2006-01-01	4152000	33917000 Derived	-29765000	347000 Derived	-30112000	-19689000 Derived	Source 2005-01-02 – 2006-01-01: 4152000 USD Inspect Revenue Open source 2005-01-02 – 2006-01-01: -29765000 USD Inspect Operating Income Open source 2005-01-02 – 2006-01-01: -30112000 USD Inspect Net Income Open source 2005-01-02 – 2006-01-01: -19018000 USD Inspect Operating Cash Flow Open source 2005-01-02 – 2006-01-01: 671000 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	6128000	41775000 Derived	-35647000	-302000 Derived	-35345000	-25731000 Derived	Source 2006-01-01 – 2006-12-31: 6128000 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: -35647000 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: -35345000 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: -24630000 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 1101000 USD Inspect Capital Expenditure Open source
2007 2006-12-31 – 2007-12-30	13896000	50320000 Derived	-36424000	-103000 Derived	-36321000	-31490000 Derived	Source 2006-12-31 – 2007-12-30: 13896000 USD Inspect Revenue Open source 2006-12-31 – 2007-12-30: -36424000 USD Inspect Operating Income Open source 2006-12-31 – 2007-12-30: -36321000 USD Inspect Net Income Open source 2006-12-31 – 2007-12-30: -29923000 USD Inspect Operating Cash Flow Open source 2006-12-31 – 2007-12-30: 1567000 USD Inspect Capital Expenditure Open source
2008 2007-12-29 – 2008-12-28	16656000	39863000 Derived	-23207000	-542000 Derived	-22665000	-18560000 Derived	Source 2007-12-29 – 2008-12-28: 16656000 USD Inspect Revenue Open source 2007-12-29 – 2008-12-28: -23207000 USD Inspect Operating Income Open source 2007-12-29 – 2008-12-28: -22665000 USD Inspect Net Income Open source 2007-12-29 – 2008-12-28: -18010000 USD Inspect Operating Cash Flow Open source 2007-12-29 – 2008-12-28: 550000 USD Inspect Capital Expenditure Open source
2010 2009-01-04 – 2010-01-03	2826000	39080000 Derived	-36254000	-9301000 Derived	-26953000	-27735000 Derived	Source 2009-01-04 – 2010-01-03: 2826000 USD Inspect Revenue Open source 2009-01-04 – 2010-01-03: -36254000 USD Inspect Operating Income Open source 2009-01-04 – 2010-01-03: -26953000 USD Inspect Net Income Open source 2009-01-04 – 2010-01-03: -27348000 USD Inspect Operating Cash Flow Open source 2009-01-04 – 2010-01-03: 387000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.8M 2010

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Revenue	12880000	Revenue: 12880000 Open source
20012001-12-30	Revenue	10379000	Revenue: 10379000 Open source
20022002-12-29	Revenue	9764000	Revenue: 9764000 Open source
20032003-12-28	Revenue	9640000	Revenue: 9640000 Open source
20052005-01-02	Revenue	6626000	Revenue: 6626000 Open source
20062006-01-01	Revenue	4152000	Revenue: 4152000 Open source
20062006-12-31	Revenue	6128000	Revenue: 6128000 Open source
20072007-12-30	Revenue	13896000	Revenue: 13896000 Open source
20082008-12-28	Revenue	16656000	Revenue: 16656000 Open source
20102010-01-03	Revenue	2826000	Revenue: 2826000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-83% 2010

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Year over year	No prior comparable period	Revenue: 12880000 Open source
20012001-12-30	Year over year	-19.4%	Revenue: 10379000 Open source Revenue: 12880000 Open source
20022002-12-29	Year over year	-5.9%	Revenue: 9764000 Open source Revenue: 10379000 Open source
20032003-12-28	Year over year	-1.3%	Revenue: 9640000 Open source Revenue: 9764000 Open source
20052005-01-02	Year over year	-31.3%	Revenue: 6626000 Open source Revenue: 9640000 Open source
20062006-01-01	Year over year	-37.3%	Revenue: 4152000 Open source Revenue: 6626000 Open source
20062006-12-31	Year over year	47.6%	Revenue: 6128000 Open source Revenue: 4152000 Open source
20072007-12-30	Year over year	126.8%	Revenue: 13896000 Open source Revenue: 6128000 Open source
20082008-12-28	Year over year	19.9%	Revenue: 16656000 Open source Revenue: 13896000 Open source
20102010-01-03	Year over year	-83%	Revenue: 2826000 Open source Revenue: 16656000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -1,282.9% 2010

Net margin -953.8% 2010

Free cash flow margin -981.4% 2010

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Operating margin	-128.8%	Operating Income: -16586000 Open source Revenue: 12880000 Open source
20012001-12-30	Operating margin	-249.6%	Operating Income: -25909000 Open source Revenue: 10379000 Open source
20022002-12-29	Operating margin	-310.5%	Operating Income: -30317000 Open source Revenue: 9764000 Open source
20032003-12-28	Operating margin	-314.5%	Operating Income: -30317000 Open source Revenue: 9640000 Open source
20052005-01-02	Operating margin	-440.6%	Operating Income: -29193000 Open source Revenue: 6626000 Open source
20062006-01-01	Operating margin	-716.9%	Operating Income: -29765000 Open source Revenue: 4152000 Open source
20062006-12-31	Operating margin	-581.7%	Operating Income: -35647000 Open source Revenue: 6128000 Open source
20072007-12-30	Operating margin	-262.1%	Operating Income: -36424000 Open source Revenue: 13896000 Open source
20082008-12-28	Operating margin	-139.3%	Operating Income: -23207000 Open source Revenue: 16656000 Open source
20102010-01-03	Operating margin	-1,282.9%	Operating Income: -36254000 Open source Revenue: 2826000 Open source
20002000-12-31	Net margin	-109.8%	Net Income: -14141000 Open source Revenue: 12880000 Open source
20012001-12-30	Net margin	-234.3%	Net Income: -24320000 Open source Revenue: 10379000 Open source
20022002-12-29	Net margin	-302.5%	Net Income: -29537000 Open source Revenue: 9764000 Open source
20032003-12-28	Net margin	-306.4%	Net Income: -29537000 Open source Revenue: 9640000 Open source
20052005-01-02	Net margin	-445.1%	Net Income: -29493000 Open source Revenue: 6626000 Open source
20062006-01-01	Net margin	-725.2%	Net Income: -30112000 Open source Revenue: 4152000 Open source
20062006-12-31	Net margin	-576.8%	Net Income: -35345000 Open source Revenue: 6128000 Open source
20072007-12-30	Net margin	-261.4%	Net Income: -36321000 Open source Revenue: 13896000 Open source
20082008-12-28	Net margin	-136.1%	Net Income: -22665000 Open source Revenue: 16656000 Open source
20102010-01-03	Net margin	-953.8%	Net Income: -26953000 Open source Revenue: 2826000 Open source
20002000-12-31	Free cash flow margin	-42.3%	Revenue: 12880000 Open source Operating Cash Flow: -3479000 Open source Capital Expenditure: 1964000 Open source
20012001-12-30	Free cash flow margin	-148.6%	Revenue: 10379000 Open source Operating Cash Flow: -11984000 Open source Capital Expenditure: 3438000 Open source
20022002-12-29	Free cash flow margin	-302.9%	Revenue: 9764000 Open source Operating Cash Flow: -23075000 Open source Capital Expenditure: 6498000 Open source
20032003-12-28	Free cash flow margin	-365.6%	Revenue: 9640000 Open source Operating Cash Flow: -31771000 Open source Capital Expenditure: 3470000 Open source
20052005-01-02	Free cash flow margin	-320.6%	Revenue: 6626000 Open source Operating Cash Flow: -19958000 Open source Capital Expenditure: 1286000 Open source
20062006-01-01	Free cash flow margin	-474.2%	Revenue: 4152000 Open source Operating Cash Flow: -19018000 Open source Capital Expenditure: 671000 Open source
20062006-12-31	Free cash flow margin	-419.9%	Revenue: 6128000 Open source Operating Cash Flow: -24630000 Open source Capital Expenditure: 1101000 Open source
20072007-12-30	Free cash flow margin	-226.6%	Revenue: 13896000 Open source Operating Cash Flow: -29923000 Open source Capital Expenditure: 1567000 Open source
20082008-12-28	Free cash flow margin	-111.4%	Revenue: 16656000 Open source Operating Cash Flow: -18010000 Open source Capital Expenditure: 550000 Open source
20102010-01-03	Free cash flow margin	-981.4%	Revenue: 2826000 Open source Operating Cash Flow: -27348000 Open source Capital Expenditure: 387000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -27.3M 2010

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Operating cash flow	-3479000	Operating Cash Flow: -3479000 Open source
20012001-12-30	Operating cash flow	-11984000	Operating Cash Flow: -11984000 Open source
20022002-12-29	Operating cash flow	-23075000	Operating Cash Flow: -23075000 Open source
20032003-12-28	Operating cash flow	-31771000	Operating Cash Flow: -31771000 Open source
20052005-01-02	Operating cash flow	-19958000	Operating Cash Flow: -19958000 Open source
20062006-01-01	Operating cash flow	-19018000	Operating Cash Flow: -19018000 Open source
20062006-12-31	Operating cash flow	-24630000	Operating Cash Flow: -24630000 Open source
20072007-12-30	Operating cash flow	-29923000	Operating Cash Flow: -29923000 Open source
20082008-12-28	Operating cash flow	-18010000	Operating Cash Flow: -18010000 Open source
20102010-01-03	Operating cash flow	-27348000	Operating Cash Flow: -27348000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -27.7M 2010

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20002000-12-31	Free cash flow	-5443000	Operating Cash Flow: -3479000 Open source Capital Expenditure: 1964000 Open source
20012001-12-30	Free cash flow	-15422000	Operating Cash Flow: -11984000 Open source Capital Expenditure: 3438000 Open source
20022002-12-29	Free cash flow	-29573000	Operating Cash Flow: -23075000 Open source Capital Expenditure: 6498000 Open source
20032003-12-28	Free cash flow	-35241000	Operating Cash Flow: -31771000 Open source Capital Expenditure: 3470000 Open source
20052005-01-02	Free cash flow	-21244000	Operating Cash Flow: -19958000 Open source Capital Expenditure: 1286000 Open source
20062006-01-01	Free cash flow	-19689000	Operating Cash Flow: -19018000 Open source Capital Expenditure: 671000 Open source
20062006-12-31	Free cash flow	-25731000	Operating Cash Flow: -24630000 Open source Capital Expenditure: 1101000 Open source
20072007-12-30	Free cash flow	-31490000	Operating Cash Flow: -29923000 Open source Capital Expenditure: 1567000 Open source
20082008-12-28	Free cash flow	-18560000	Operating Cash Flow: -18010000 Open source Capital Expenditure: 550000 Open source
20102010-01-03	Free cash flow	-27735000	Operating Cash Flow: -27348000 Open source Capital Expenditure: 387000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

186.5% 2010

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Liabilities / assets	14.6%	Total Liabilities: 19560000 Open source Total Assets: 134403000 Open source
20012001-12-30	Liabilities / assets	15.4%	Total Liabilities: 18493000 Open source Total Assets: 120443000 Open source
20022002-12-29	Liabilities / assets	27.9%	Total Liabilities: 26601000 Open source Total Assets: 95373000 Open source
20032003-12-28	Liabilities / assets	32.2%	Total Liabilities: 22911000 Open source Total Assets: 71072000 Open source
20052005-01-02	Liabilities / assets	41.3%	Total Liabilities: 23648000 Open source Total Assets: 57301000 Open source
20062006-01-01	Liabilities / assets	45%	Total Liabilities: 30010000 Open source Total Assets: 66719000 Open source
20062006-12-31	Liabilities / assets	48.2%	Total Liabilities: 35279000 Open source Total Assets: 73235000 Open source
20072007-12-30	Liabilities / assets	80.3%	Total Liabilities: 32689000 Open source Total Assets: 40713000 Open source
20082008-12-28	Liabilities / assets	110.2%	Total Liabilities: 44526000 Open source Total Assets: 40403000 Open source
20102010-01-03	Liabilities / assets	186.5%	Total Liabilities: 48484000 Open source Total Assets: 26000000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.33× 2010

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20002000-12-31	Current assets / current liabilities	5.59×	Current Assets: 107655000 Open source Current Liabilities: 19266000 Open source
20012001-12-30	Current assets / current liabilities	5.04×	Current Assets: 92871000 Open source Current Liabilities: 18413000 Open source
20022002-12-29	Current assets / current liabilities	4.46×	Current Assets: 61460000 Open source Current Liabilities: 13778000 Open source
20032003-12-28	Current assets / current liabilities	3.32×	Current Assets: 34296000 Open source Current Liabilities: 10329000 Open source
20052005-01-02	Current assets / current liabilities	1.74×	Current Assets: 24951000 Open source Current Liabilities: 14312000 Open source
20062006-01-01	Current assets / current liabilities	1.92×	Current Assets: 38923000 Open source Current Liabilities: 20322000 Open source
20062006-12-31	Current assets / current liabilities	2.56×	Current Assets: 48218000 Open source Current Liabilities: 18836000 Open source
20072007-12-30	Current assets / current liabilities	0.91×	Current Assets: 16979000 Open source Current Liabilities: 18719000 Open source
20082008-12-28	Current assets / current liabilities	0.86×	Current Assets: 13755000 Open source Current Liabilities: 16057000 Open source
20102010-01-03	Current assets / current liabilities	0.33×	Current Assets: 7431000 Open source Current Liabilities: 22860000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2000 2000-01-01 – 2000-12-31	−USD 14.14 million Exact value Exact value: -14141000 USD 2000-01-01 – 2000-12-31: -14141000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2000-12-31 rEVO Biologics, Inc. (edgar:904973) Net Income: -14141000 USD Concept: fundies:NetIncome Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14141000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-03-010847.txt#4532 The citation records this snapshot. The page link may show a newer release later.	−USD 3.48 million Exact value Exact value: -3479000 USD 2000-01-01 – 2000-12-31: -3479000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2000-12-31 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -3479000 USD Concept: fundies:OperatingCashFlow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3479000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-03-010847.txt#6395 The citation records this snapshot. The page link may show a newer release later.	USD 1.96 million Exact value Exact value: 1964000 USD 2000-01-01 – 2000-12-31: 1964000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2000-12-31 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 1964000 USD Concept: fundies:CapitalExpenditure Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2000-12-31&surface=latest&period_type=duration&start=2000-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1964000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-03-010847.txt#6423 The citation records this snapshot. The page link may show a newer release later.	−USD 5.44 million Calculation and evidence -3479000 − 1964000 USD Exact free cash flow: -5443000 USD 2000-01-01 – 2000-12-31: -3479000 USD · Inspect Operating Cash Flow · Source 2000-01-01 – 2000-12-31: 1964000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2000-12-31 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -5443000 USD Concept: free-cash-flow Period: 2000-01-01 to 2000-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3479000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-03-010847.txt#6395 Input fundies:CapitalExpenditure: 1964000 USD (2000-01-01 to 2000-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-03-010847.txt#6423 The citation records this snapshot. The page link may show a newer release later.
2001 2000-12-31 – 2001-12-30	−USD 24.32 million Exact value Exact value: -24320000 USD 2000-12-31 – 2001-12-30: -24320000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2001-12-30 rEVO Biologics, Inc. (edgar:904973) Net Income: -24320000 USD Concept: fundies:NetIncome Period: 2000-12-31 to 2001-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2001-12-30&surface=latest&period_type=duration&start=2000-12-31&unit=USD&dimensions= Input fundies:NetIncome: -24320000 USD (2000-12-31 to 2001-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-05-050638.txt#3924 The citation records this snapshot. The page link may show a newer release later.	−USD 11.98 million Exact value Exact value: -11984000 USD 2000-12-31 – 2001-12-30: -11984000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2001-12-30 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -11984000 USD Concept: fundies:OperatingCashFlow Period: 2000-12-31 to 2001-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2001-12-30&surface=latest&period_type=duration&start=2000-12-31&unit=USD&dimensions= Input fundies:OperatingCashFlow: -11984000 USD (2000-12-31 to 2001-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-04-006861.txt#6325 The citation records this snapshot. The page link may show a newer release later.	USD 3.44 million Exact value Exact value: 3438000 USD 2000-12-31 – 2001-12-30: 3438000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2001-12-30 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 3438000 USD Concept: fundies:CapitalExpenditure Period: 2000-12-31 to 2001-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2001-12-30&surface=latest&period_type=duration&start=2000-12-31&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3438000 USD (2000-12-31 to 2001-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-04-006861.txt#6353 The citation records this snapshot. The page link may show a newer release later.	−USD 15.42 million Calculation and evidence -11984000 − 3438000 USD Exact free cash flow: -15422000 USD 2000-12-31 – 2001-12-30: -11984000 USD · Inspect Operating Cash Flow · Source 2000-12-31 – 2001-12-30: 3438000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2001-12-30 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -15422000 USD Concept: free-cash-flow Period: 2000-12-31 to 2001-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -11984000 USD (2000-12-31 to 2001-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-04-006861.txt#6325 Input fundies:CapitalExpenditure: 3438000 USD (2000-12-31 to 2001-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-04-006861.txt#6353 The citation records this snapshot. The page link may show a newer release later.
2002 2001-12-30 – 2002-12-29	−USD 29.54 million Exact value Exact value: -29537000 USD 2001-12-30 – 2002-12-29: -29537000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2002-12-29 rEVO Biologics, Inc. (edgar:904973) Net Income: -29537000 USD Concept: fundies:NetIncome Period: 2001-12-30 to 2002-12-29 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2002-12-29&surface=latest&period_type=duration&start=2001-12-30&unit=USD&dimensions= Input fundies:NetIncome: -29537000 USD (2001-12-30 to 2002-12-29) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#4712 The citation records this snapshot. The page link may show a newer release later.	−USD 23.08 million Exact value Exact value: -23075000 USD 2001-12-30 – 2002-12-29: -23075000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2002-12-29 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -23075000 USD Concept: fundies:OperatingCashFlow Period: 2001-12-30 to 2002-12-29 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2002-12-29&surface=latest&period_type=duration&start=2001-12-30&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23075000 USD (2001-12-30 to 2002-12-29) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-05-050638.txt#5277 The citation records this snapshot. The page link may show a newer release later.	USD 6.5 million Exact value Exact value: 6498000 USD 2001-12-30 – 2002-12-29: 6498000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2002-12-29 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 6498000 USD Concept: fundies:CapitalExpenditure Period: 2001-12-30 to 2002-12-29 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2002-12-29&surface=latest&period_type=duration&start=2001-12-30&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6498000 USD (2001-12-30 to 2002-12-29) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-05-050638.txt#5305 The citation records this snapshot. The page link may show a newer release later.	−USD 29.57 million Calculation and evidence -23075000 − 6498000 USD Exact free cash flow: -29573000 USD 2001-12-30 – 2002-12-29: -23075000 USD · Inspect Operating Cash Flow · Source 2001-12-30 – 2002-12-29: 6498000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2002-12-29 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -29573000 USD Concept: free-cash-flow Period: 2001-12-30 to 2002-12-29 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23075000 USD (2001-12-30 to 2002-12-29) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-05-050638.txt#5277 Input fundies:CapitalExpenditure: 6498000 USD (2001-12-30 to 2002-12-29) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-05-050638.txt#5305 The citation records this snapshot. The page link may show a newer release later.
2003 2002-12-29 – 2003-12-28	−USD 29.54 million Exact value Exact value: -29537000 USD 2002-12-29 – 2003-12-28: -29537000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2003-12-28 rEVO Biologics, Inc. (edgar:904973) Net Income: -29537000 USD Concept: fundies:NetIncome Period: 2002-12-29 to 2003-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2003-12-28&surface=latest&period_type=duration&start=2002-12-29&unit=USD&dimensions= Input fundies:NetIncome: -29537000 USD (2002-12-29 to 2003-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001047469-04-006861.txt#5134 The citation records this snapshot. The page link may show a newer release later.	−USD 31.77 million Exact value Exact value: -31771000 USD 2002-12-29 – 2003-12-28: -31771000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2003-12-28 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -31771000 USD Concept: fundies:OperatingCashFlow Period: 2002-12-29 to 2003-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2003-12-28&surface=latest&period_type=duration&start=2002-12-29&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31771000 USD (2002-12-29 to 2003-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#6200 The citation records this snapshot. The page link may show a newer release later.	USD 3.47 million Exact value Exact value: 3470000 USD 2002-12-29 – 2003-12-28: 3470000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2003-12-28 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 3470000 USD Concept: fundies:CapitalExpenditure Period: 2002-12-29 to 2003-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2003-12-28&surface=latest&period_type=duration&start=2002-12-29&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3470000 USD (2002-12-29 to 2003-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#6228 The citation records this snapshot. The page link may show a newer release later.	−USD 35.24 million Calculation and evidence -31771000 − 3470000 USD Exact free cash flow: -35241000 USD 2002-12-29 – 2003-12-28: -31771000 USD · Inspect Operating Cash Flow · Source 2002-12-29 – 2003-12-28: 3470000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2003-12-28 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -35241000 USD Concept: free-cash-flow Period: 2002-12-29 to 2003-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31771000 USD (2002-12-29 to 2003-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#6200 Input fundies:CapitalExpenditure: 3470000 USD (2002-12-29 to 2003-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#6228 The citation records this snapshot. The page link may show a newer release later.
2005 2004-01-03 – 2005-01-02	−USD 29.49 million Exact value Exact value: -29493000 USD 2004-01-03 – 2005-01-02: -29493000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2005-01-02 rEVO Biologics, Inc. (edgar:904973) Net Income: -29493000 USD Concept: fundies:NetIncome Period: 2004-01-03 to 2005-01-02 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2005-01-02&surface=latest&period_type=duration&start=2004-01-03&unit=USD&dimensions= Input fundies:NetIncome: -29493000 USD (2004-01-03 to 2005-01-02) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-06-054015.txt#4712 The citation records this snapshot. The page link may show a newer release later.	−USD 19.96 million Exact value Exact value: -19958000 USD 2004-01-03 – 2005-01-02: -19958000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2005-01-02 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -19958000 USD Concept: fundies:OperatingCashFlow Period: 2004-01-03 to 2005-01-02 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2005-01-02&surface=latest&period_type=duration&start=2004-01-03&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19958000 USD (2004-01-03 to 2005-01-02) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-07-048522.txt#6427 The citation records this snapshot. The page link may show a newer release later.	USD 1.29 million Exact value Exact value: 1286000 USD 2004-01-03 – 2005-01-02: 1286000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2005-01-02 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 1286000 USD Concept: fundies:CapitalExpenditure Period: 2004-01-03 to 2005-01-02 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2005-01-02&surface=latest&period_type=duration&start=2004-01-03&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1286000 USD (2004-01-03 to 2005-01-02) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-07-048522.txt#6455 The citation records this snapshot. The page link may show a newer release later.	−USD 21.24 million Calculation and evidence -19958000 − 1286000 USD Exact free cash flow: -21244000 USD 2004-01-03 – 2005-01-02: -19958000 USD · Inspect Operating Cash Flow · Source 2004-01-03 – 2005-01-02: 1286000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2005-01-02 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -21244000 USD Concept: free-cash-flow Period: 2004-01-03 to 2005-01-02 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19958000 USD (2004-01-03 to 2005-01-02) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-07-048522.txt#6427 Input fundies:CapitalExpenditure: 1286000 USD (2004-01-03 to 2005-01-02) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-07-048522.txt#6455 The citation records this snapshot. The page link may show a newer release later.
2006 2005-01-02 – 2006-01-01	−USD 30.11 million Exact value Exact value: -30112000 USD 2005-01-02 – 2006-01-01: -30112000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2006-01-01 rEVO Biologics, Inc. (edgar:904973) Net Income: -30112000 USD Concept: fundies:NetIncome Period: 2005-01-02 to 2006-01-01 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2006-01-01&surface=latest&period_type=duration&start=2005-01-02&unit=USD&dimensions= Input fundies:NetIncome: -30112000 USD (2005-01-02 to 2006-01-01) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-08-048711.txt#4461 The citation records this snapshot. The page link may show a newer release later.	−USD 19.02 million Exact value Exact value: -19018000 USD 2005-01-02 – 2006-01-01: -19018000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2006-01-01 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -19018000 USD Concept: fundies:OperatingCashFlow Period: 2005-01-02 to 2006-01-01 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2006-01-01&surface=latest&period_type=duration&start=2005-01-02&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19018000 USD (2005-01-02 to 2006-01-01) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-08-048711.txt#6077 The citation records this snapshot. The page link may show a newer release later.	USD 671,000 Exact value Exact value: 671000 USD 2005-01-02 – 2006-01-01: 671000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2006-01-01 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 671000 USD Concept: fundies:CapitalExpenditure Period: 2005-01-02 to 2006-01-01 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2006-01-01&surface=latest&period_type=duration&start=2005-01-02&unit=USD&dimensions= Input fundies:CapitalExpenditure: 671000 USD (2005-01-02 to 2006-01-01) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-08-048711.txt#6105 The citation records this snapshot. The page link may show a newer release later.	−USD 19.69 million Calculation and evidence -19018000 − 671000 USD Exact free cash flow: -19689000 USD 2005-01-02 – 2006-01-01: -19018000 USD · Inspect Operating Cash Flow · Source 2005-01-02 – 2006-01-01: 671000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2006-01-01 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -19689000 USD Concept: free-cash-flow Period: 2005-01-02 to 2006-01-01 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19018000 USD (2005-01-02 to 2006-01-01) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-08-048711.txt#6077 Input fundies:CapitalExpenditure: 671000 USD (2005-01-02 to 2006-01-01) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-08-048711.txt#6105 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	−USD 35.35 million Exact value Exact value: -35345000 USD 2006-01-01 – 2006-12-31: -35345000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2006-12-31 rEVO Biologics, Inc. (edgar:904973) Net Income: -35345000 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35345000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-09-040458.txt#4792 The citation records this snapshot. The page link may show a newer release later.	−USD 24.63 million Exact value Exact value: -24630000 USD 2006-01-01 – 2006-12-31: -24630000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2006-12-31 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -24630000 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24630000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-09-040458.txt#6387 The citation records this snapshot. The page link may show a newer release later.	USD 1.1 million Exact value Exact value: 1101000 USD 2006-01-01 – 2006-12-31: 1101000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2006-12-31 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 1101000 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1101000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-09-040458.txt#6415 The citation records this snapshot. The page link may show a newer release later.	−USD 25.73 million Calculation and evidence -24630000 − 1101000 USD Exact free cash flow: -25731000 USD 2006-01-01 – 2006-12-31: -24630000 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 1101000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2006-12-31 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -25731000 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24630000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-09-040458.txt#6387 Input fundies:CapitalExpenditure: 1101000 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-09-040458.txt#6415 The citation records this snapshot. The page link may show a newer release later.
2007 2006-12-31 – 2007-12-30	−USD 36.32 million Exact value Exact value: -36321000 USD 2006-12-31 – 2007-12-30: -36321000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2007-12-30 rEVO Biologics, Inc. (edgar:904973) Net Income: -36321000 USD Concept: fundies:NetIncome Period: 2006-12-31 to 2007-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2007-12-30&surface=latest&period_type=duration&start=2006-12-31&unit=USD&dimensions= Input fundies:NetIncome: -36321000 USD (2006-12-31 to 2007-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#5169 The citation records this snapshot. The page link may show a newer release later.	−USD 29.92 million Exact value Exact value: -29923000 USD 2006-12-31 – 2007-12-30: -29923000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2007-12-30 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -29923000 USD Concept: fundies:OperatingCashFlow Period: 2006-12-31 to 2007-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-30&surface=latest&period_type=duration&start=2006-12-31&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29923000 USD (2006-12-31 to 2007-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 The citation records this snapshot. The page link may show a newer release later.	USD 1.57 million Exact value Exact value: 1567000 USD 2006-12-31 – 2007-12-30: 1567000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2007-12-30 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 1567000 USD Concept: fundies:CapitalExpenditure Period: 2006-12-31 to 2007-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-30&surface=latest&period_type=duration&start=2006-12-31&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1567000 USD (2006-12-31 to 2007-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.	−USD 31.49 million Calculation and evidence -29923000 − 1567000 USD Exact free cash flow: -31490000 USD 2006-12-31 – 2007-12-30: -29923000 USD · Inspect Operating Cash Flow · Source 2006-12-31 – 2007-12-30: 1567000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2007-12-30 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -31490000 USD Concept: free-cash-flow Period: 2006-12-31 to 2007-12-30 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29923000 USD (2006-12-31 to 2007-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 Input fundies:CapitalExpenditure: 1567000 USD (2006-12-31 to 2007-12-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.
2008 2007-12-29 – 2008-12-28	−USD 22.67 million Exact value Exact value: -22665000 USD 2007-12-29 – 2008-12-28: -22665000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2008-12-28 rEVO Biologics, Inc. (edgar:904973) Net Income: -22665000 USD Concept: fundies:NetIncome Period: 2007-12-29 to 2008-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2008-12-28&surface=latest&period_type=duration&start=2007-12-29&unit=USD&dimensions= Input fundies:NetIncome: -22665000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#5169 The citation records this snapshot. The page link may show a newer release later.	−USD 18.01 million Exact value Exact value: -18010000 USD 2007-12-29 – 2008-12-28: -18010000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2008-12-28 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -18010000 USD Concept: fundies:OperatingCashFlow Period: 2007-12-29 to 2008-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-28&surface=latest&period_type=duration&start=2007-12-29&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18010000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 The citation records this snapshot. The page link may show a newer release later.	USD 550,000 Exact value Exact value: 550000 USD 2007-12-29 – 2008-12-28: 550000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2008-12-28 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 550000 USD Concept: fundies:CapitalExpenditure Period: 2007-12-29 to 2008-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-28&surface=latest&period_type=duration&start=2007-12-29&unit=USD&dimensions= Input fundies:CapitalExpenditure: 550000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.	−USD 18.56 million Calculation and evidence -18010000 − 550000 USD Exact free cash flow: -18560000 USD 2007-12-29 – 2008-12-28: -18010000 USD · Inspect Operating Cash Flow · Source 2007-12-29 – 2008-12-28: 550000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2008-12-28 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -18560000 USD Concept: free-cash-flow Period: 2007-12-29 to 2008-12-28 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18010000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 Input fundies:CapitalExpenditure: 550000 USD (2007-12-29 to 2008-12-28) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.
2010 2009-01-04 – 2010-01-03	−USD 26.95 million Exact value Exact value: -26953000 USD 2009-01-04 – 2010-01-03: -26953000 USD Inspect Net Income Open source Share or cite Citation for Net Income · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Net Income: -26953000 USD Concept: fundies:NetIncome Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ANetIncome&period=2010-01-03&surface=latest&period_type=duration&start=2009-01-04&unit=USD&dimensions= Input fundies:NetIncome: -26953000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#5169 The citation records this snapshot. The page link may show a newer release later.	−USD 27.35 million Exact value Exact value: -27348000 USD 2009-01-04 – 2010-01-03: -27348000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Operating Cash Flow: -27348000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3AOperatingCashFlow&period=2010-01-03&surface=latest&period_type=duration&start=2009-01-04&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27348000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 The citation records this snapshot. The page link may show a newer release later.	USD 387,000 Exact value Exact value: 387000 USD 2009-01-04 – 2010-01-03: 387000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Capital Expenditure: 387000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973/explain?concept=fundies%3ACapitalExpenditure&period=2010-01-03&surface=latest&period_type=duration&start=2009-01-04&unit=USD&dimensions= Input fundies:CapitalExpenditure: 387000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.	−USD 27.74 million Calculation and evidence -27348000 − 387000 USD Exact free cash flow: -27735000 USD 2009-01-04 – 2010-01-03: -27348000 USD · Inspect Operating Cash Flow · Source 2009-01-04 – 2010-01-03: 387000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · rEVO Biologics, Inc. · 2010-01-03 rEVO Biologics, Inc. (edgar:904973) Free cash flow: -27735000 USD Concept: free-cash-flow Period: 2009-01-04 to 2010-01-03 Values: Latest reported Published: 2026-11-02T11:54:01Z Snapshot: 7ec3776b1086194e1be37aed54cd06568891eaee4d6ff4b3090d5b728b90d4d5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/904973?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27348000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6933 Input fundies:CapitalExpenditure: 387000 USD (2009-01-04 to 2010-01-03) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/904973/0001193125-10-054939.txt#6961 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

64 filings · 0 latest values · 0 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000904973, 904973, edgar:904973

Also known as GENZYME TRANSGENICS CORP, GTC BIOTHERAPEUTICS INC

rEVO Biologics, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2010 2009-01-04 – 2010-01-03

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation